



Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") and Stall Courant, owned by Unibet founder Anders Ström and run by trotting trainer Sabine Kagebrant, have signed an agreement regarding a three-month pilot test of the LAMPlify® platform.

Stall Courant, founded in 2005 and located in Heby, Sweden, is home to 35 trotting horses and also operates a breeding program. Sabine Kagebrant joined Stall Courant in 2014 and has served as CEO since 2016. Together with the trotting horse Joviality, Kagebrant has secured victories in several major races.

"We at Stall Courant are excited to work with Diagonal Bio to evaluate LAMPlify. We want to improve the overall equine health and if LAMPlify proves to be a tool we can use for early detection of potential viral infections in our horses, we can prevent the short- and long-term effects the infections have." – Sabine Kagebrant, CEO of Stall Courant

"I am glad to announce the agreement to conduct a pilot test of LAMPlify with Stall Courant, a respected player in the market. This pilot test represents another important step in demonstrating the value of our technology in a real-world setting. We look forward to working closely with our partner and gaining valuable insights and I am confident Sabine and Stall Courant will appreciate what LAMPlify can do for them." – Karin Wehlin, CEO of Diagonal Bio AB (publ)

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 13 March, 2025, at 09:45 CET.

For additional information about Diagonal Bio, please contact:

Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.